Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential (Q39741000)

14 September 2017

Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential (English)

1 reference

14 September 2017

1 reference

Geoffrey M Kuesters

1

1 reference

PubMed ID

20148631

14 September 2017

Robert B Campbell

series ordinal

2

1 reference

14 September 2017

1 February 2010

1 reference

14 September 2017

1 reference

14 September 2017

5

1 reference

14 September 2017

2

1 reference

14 September 2017

181-192

1 reference

Endothelial cell proliferation as a novel approach to targeting tumour therapy

14 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Tumor physiology and delivery of nanopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Neuropilins: structure, function and role in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Evolution of bevacizumab-based therapy in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Targeting of skeletal muscle in vitro using biotinylated immunoliposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

HMEC-1: establishment of an immortalized human microvascular endothelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

New colorimetric cytotoxicity assay for anticancer-drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.09.105

21 January 2018

Identifiers

DOI

10.2217/NNM.09.105

1 reference

14 September 2017

1 reference

PubMed ID

20148631